Literature DB >> 16433937

Von Willebrand disease.

Andra H James1.   

Abstract

UNLABELLED: Von Willebrand disease (VWD), the most common inherited bleeding disorder, results from a deficiency of von Willebrand factor (VWF), a protein required for the normal adhesion of platelets to the site of injured endothelium and for preservation of factor VIII in the circulation. The prevalence of VWD has been reported to be as high as 1.3%. Among women with VWD, menorrhagia is the most common symptom, affecting 32% to 100%. Treatments that have been reported to control menorrhagia in these women include combined oral contraceptives, 1-deamino-8-D-arginine vasopressin (DDAVP), tranexamic acid, and the levonorgestrel-releasing intrauterine system. With the exception of nonsteroidal antiinflammatory drugs, any treatments effective in the treatment of menorrhagia, including hysterectomy, may be suitable. Besides menorrhagia, women with VWD appear to be at an increased risk of developing hemorrhagic ovarian cysts and possibly endometriosis. As they grow older, they may be more likely to manifest conditions that present with bleeding such as fibroids, endometrial hyperplasia, and polyps. During pregnancy, they may be at greater risk of miscarriage and bleeding complications, particularly delayed or secondary postpartum hemorrhage. Vaginal or vulvar hematomas, extremely rare in women without bleeding disorders, are not uncommon. Although women with VWD are at risk for the same obstetric and gynecologic problems that affect all women, they appear to be disproportionately affected by conditions that manifest with bleeding. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING
OBJECTIVES: After completion of this article, the reader should be able to recall that Von Willebrand Disease (VWD) is a common inherited disease, especially in women with menorrhagia; state that prophylaxis therapies against bleeding in pregnant and nonpregnant women are available; and explain that, despite prophylaxis, miscarriage and bleeding complications can still occur.

Entities:  

Mesh:

Year:  2006        PMID: 16433937     DOI: 10.1097/01.ogx.0000197818.94002.91

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  5 in total

1.  IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome.

Authors:  Christin R Howard; Tara L Lin; Mark T Cunningham; Brea C Lipe
Journal:  Blood Coagul Fibrinolysis       Date:  2014-09       Impact factor: 1.276

Review 2.  [Coagulation management in geriatric surgery].

Authors:  H Eichler
Journal:  Chirurg       Date:  2017-02       Impact factor: 0.955

3.  The Effect of Von Willebrand Disease on Pregnancy, Delivery, and Postpartum Period: A Retrospective Observational Study.

Authors:  Mateja Sladič; Ivan Verdenik; Špela Smrkolj
Journal:  Medicina (Kaunas)       Date:  2022-06-07       Impact factor: 2.948

4.  Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.

Authors:  Nicoletta Machin; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-07-28

5.  Gingival enlargement in von Willebrand disease: A case report.

Authors:  Prabhati Gupta; Suhail M Jan; Roobal Behal; Gowhar Nazir
Journal:  J Indian Soc Periodontol       Date:  2014-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.